The Board of Directors of the Finnish biotech company FIT Biotech has decided to file an application for bankruptcy, reports Huvudstadsbladet. The reason behind the decision is that a financing

The company reports that a collaboration agreement with the Centre for Skin Sciences (CSS) at University of Bradford, UK, has been signed. The aim is to combine in vitro experiments with the

The company has taken its first investment capital and a cunning business development partner. It is Nordiska Centrumhus that shares the Quretech Bio vision regarding new drugs against infectious diseases

The Swedish clinical CRO CTC Clinical Trial Consultants will conduct Spago’s first clinical study with SpagoPix. The aim of the clinical trial is to document safety and MR images in

Keensight Capital hopes to mobilize significant resources to help the management team to implement a strategic development plan to become a European leader. “We are very pleased to team up

Nordic Life Science asked Lars Hedbys, CEO of Idogen, about the potential and challenges for cell therapies. For gene and cell therapies 2017 really was a breakthrough year. For example, there

Luigi Costa will step down as Chief Executive Officer by mutual agreement with the Board of Directors. “Nordic Nanovector has recently taken a significant hit to its market valuation and

Xbrane Biopharma and China Resource Pharmaceutical Group Limited have entered into a license agreement which gives CR Pharma exclusive rights to market and sell Spherotide (Triptorelin, a GnRH analogue in

Alligator Biosciencehas appointed Theradex Oncology as CRO for their planned phase I study of ATOR-1015 for the treatment of metastatic cancer. The upcoming clinical phase I study with ATOR-1015 is

Cytovation has raised NOK 10m in a private funding round, completing the second stage of fundraising, having raised NOK 20m in June 2017. Both financings were led by a group

Alligator Bioscience announces that a development milestone payment of USD 6 million has been triggered under the partnership agreement for ADC-1013 (JNJ-64457107) with Janssen Biotech, Inc. The milestone payment is for the

According to a new analysis from RAND Corp, introducing biosimilar versions of complex biologic drugs could cut healthcare spending in the US by $54 billion over the next decade. The

Finnish DelSiTech and Korean C-Tri have signed a partnership and collaboration agreement to develop long-acting controlled release formulations with significant commercial potential. The first C-Tri product being developed in this

Biotech company Immuneed has published two scientific publications, supporting both its immuno-service and its immuno-oncology offerings. The articles demonstrate Immuneed’s whole blood loop assay, a tool to predict first-infusion reactions

Yesterday, Oncoinvent held an opening ceremony for its new production and lab facilities. The new production facility contains a Grade B clean room, two Category B type isotope production suites,

Alligator Bioscience announces the expansion of its management team with the appointment of Charlotte A Russell, MD, PhD, as Chief Medical Officer and Peter Ellmark, PhD, Associate professor, as Vice

BioInvent International and Transgene have entered a collaboration to co-develop next generation oncolytic virus (OV) candidates encoding an anti-CTLA-4 antibody sequence – potentially with additional transgenes – capable of treating

Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is traditional hard work. The two long-time friends, who came to

BioInvent announces its plans to expand the therapeutic potential of its lead antibody BI-1206. The current development program will be expanded with an open, single-arm Phase I/IIa clinical study to

ExpreS2ion’s new joint venture, AdaptVac, reaches proof of concept in advanced animal models (POCA) for AV-001, its novel vaccine treatment against breast cancer tumours. The scientific results that form the

BioArctic announces that the European Patent Office (EPO) has decided to grant a European patent (EP2539366) to BioArctic AB and the patent will be published on November 08, 2017. The European

Athera Biotechnologies has announced that two composition of matter patents have been allowed for antibodies with binding to phosphorylcholine, PC. The PC target is part of modified phospholipids and has